Method for the treatment of multiple sclerosis by inhibiting IL-17 activity

Details for Australian Patent Application No. 2004292393 (hide)

International Classifications

Event Publications

15 June 2006 PCT application entered the National Phase

PCT publication WO2005/051422 Priority application(s): WO2005/051422

14 February 2008 Assignment before Grant

Celltech R&D Limited The application has been assigned to UCB Pharma S.A.

8 October 2009 Application Accepted

Published as AU-B-2004292393

21 January 2010 Opposition Lodged

Schering Corporation has lodged an opposition against UCB Pharma S.A.

14 April 2011 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 10 Jan 2011. Address for service in Australia - Watermark Patent and Trade Marks Attorneys Level 2 302 Burwood Road Hawthorn VIC 3122

4 August 2011 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 10 Jan 2011 2005

19 January 2012 Opposition Withdrawn

The opposition by Schering Corporation against UCB Pharma S.A has been withdrawn.

8 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.